Alto Neuroscience Positive Phase 1 Results for Schizophrenia Inhibitor

 ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated with PDE4 inhibitors –

– First-in-human achievement of target exposure with proprietary transdermal patch formulation developed in partnership with MEDRx –

– Proof-of-concept study in cognitive impairment associated with schizophrenia (CIAS) to be initiated in the first half of 2024 –

https://www.businesswire.com/news/home/20240423861340/en/The